CVLLY (CellaVision AB) EPS without NRI: $0.30 (TTM As of Mar. 2026)


CVLLY CellaVision AB CVLLY
69 GF Score
Price $7.06
GF Value $12.48
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is CellaVision AB EPS without NRI?

CellaVision AB CVLLY +12.06% 69 EPS without NRI is $0.30 as of Mar. 2026. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 667 Medical Devices & Instruments companies, CellaVision AB ranks better than 51.87% on this metric.

CellaVision AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30.

During the past 12 months, CellaVision AB's average earnings per share (NRI) Growth Rate was -11.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 9.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 9.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for CellaVision AB's EPS without NRI or its related term are showing as below:

CVLLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.5   Med: 12.75   Max: 144.6
Current: 9

During the past 13 years, CellaVision AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 144.60% per year. The lowest was -38.50% per year. And the median was 12.75% per year.

CVLLY's 3-Year EPS without NRI Growth Rate is ranked better than
51.87% of 667 companies
in the Medical Devices & Instruments industry
Industry Median: 8 vs CVLLY: 9.00

CellaVision AB's EPS (Diluted) for the three months ended in Mar. 2026 was $0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30.

CellaVision AB's EPS (Basic) for the three months ended in Mar. 2026 was $0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30.


CellaVision AB  (OTCPK:CVLLY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CellaVision AB EPS without NRI Related Terms


CellaVision AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for CellaVision AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB EPS without NRI Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.24 0.27 0.27 0.35

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.08 0.07 0.10 0.05

CVLLY vs ABT, SYK, MDT: EPS without NRI Comparison

For the Medical Devices subindustry, CellaVision AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where CellaVision AB's PE Ratio without NRI falls into.


CVLLY
69GF Score
CellaVision AB CVLLY
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.30 mean?
CellaVision AB (CVLLY) has a EPS without NRI of $0.30 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on CellaVision AB and its competitors. According to the industry distribution chart, CellaVision AB ranks #321 out of 667 companies in the Medical Devices & Instruments industry, placing it in the top 48.1%.
Is CellaVision AB's EPS without NRI too high?
CellaVision AB's current EPS without NRI is $0.30. The Medical Devices & Instruments industry median EPS without NRI is 8.00. CellaVision AB's value of $0.30 is 96.3% below this industry median. Based on the distribution chart, CellaVision AB ranks #321 out of 667 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #321 out of 667 companies for EPS without NRI. This puts CellaVision AB in the upper half of its industry. The industry median EPS without NRI is 8.00. CellaVision AB's value of $0.30 is 96.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.00, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current EPS without NRI of $0.30 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current EPS without NRI is $0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current EPS without NRI is $0.30 and 96.3% below the Medical Devices & Instruments industry median of 8.00. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current EPS without NRI is $0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CVLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48. GuruFocus considers CellaVision AB to be Significantly Undervalued.

Key valuation signals for CVLLY:

  • EPS without NRI: $0.30
  • GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
  • GF Score™: 69/100 with 1 warning sign
  • Industry Position: 96.3% below the Medical Devices & Instruments median (#321 of 667)

No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score

Get the complete analysis for CVLLY

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06
Price
$12.48
GF Value